Abstract
Background Differentiating risk for HIV infection is important for providing focussed prevention options to individuals. We conducted a longitudinal study to validate a risk-differentiation tool for predicting HIV or HSV-2 acquisition among HIV-negative youth.
Setting Population-based household survey in east Zimbabwe.
Methods HIV and HSV-2 status and HIV behavioural risk factors were assessed in two surveys conducted 12 months apart among young people. Associations between risk-behaviours and combined HIV/HSV-2 incident infection were estimated using proportional hazards models. We calculated the sensitivity and specificity of risk-differentiation questions in predicting HIV/HSV-2 acquisition and quantified changes between surveys among low, medium, and high-risk categories.
Results In total, 44 HIV/HSV-2 seroconversions were observed in 1812 person-years of follow up (2.43/100PY, 95%CI: 1.71-3.15); 50% of incident cases reported never having had sex at baseline. Risk of HIV/HSV-2 acquisition was higher for those reporting non-regular partners (women: HR=2.71, 95% CI:1.12-6.54, men: HR=1.37, 95%CI: 0.29-6.38) and those reporting having a partner with a sexually transmitted infection (STI) (HR=7.62 (1.22-47.51). Adding a question on non-regular partnerships increased tool sensitivity from 18.2% to 38.6%, and further to 77.3% when restricted to those who had ever had sex. Individual risk category increased for 28% of men and 17% of women over 12-months.
Conclusion The refined risk differentiation tool identified a high proportion of youth at risk of HIV acquisition. Despite this, half of incident infections were among individuals who reported no prior sexual activity. The shifting patterns of risk behaviours underscore the need for dynamic prevention engagement strategies in high HIV prevalence or incidence settings.
Competing Interest Statement
Simon Gregson declares shareholdings in pharmaceutical companies GlaxoSmithKline and Astra Zeneca. All other authors have no conflicts of interest to declare. The WHO was involved in study design and data interpretation.
Funding Statement
This work was supported by the World Health Organization (ERC.0003077 2019), the Bill and Melinda Gates Foundation (BMGF) (INV09999) and the National Institute of Mental Health (NIMH) (R01MH11456201). LM, SG, JWI-E and CN acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Medical Research Council of Zimbabwe, the Imperial College Research Ethics Committee (17IC4160), and the World Health Organization Ethics Review Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of Interest and Funding Sources This work was supported by the World Health Organization (ERC.0003077 2019), the Bill and Melinda Gates Foundation (BMGF) (INV-09999) and the National Institute of Mental Health (NIMH) (R01MH114562–01). LM, SG, JWI-E and CN acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking.
SG declares shareholdings in pharmaceutical companies GlaxoSmithKline and Astra Zeneca. All other authors have no conflicts of interest to declare. The WHO was involved in study design and data interpretation.
For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) license to any Author Accepted Manuscript version arising.
Data Availability
Due to the sensitive nature of data collected, including information on HIV status, treatment and sexual risk behaviour, the Manicaland Centre for Public Health does not make full analysis datasets publicly available. Summary datasets of household and background sociodemographic individual questionnaire data, covering rounds 1-8 (1998-2021), are publicly available for download via the Manicaland Centre for Public Health website here - http://www.manicalandhivproject.org/data-access.html. Quantitative data used for analyses produced by the Manicaland Centre for Public Health are available on request following completion of a data access request form here - http://www.manicalandhivproject.org/data-access.html. Additionally, summary HIV incidence and mortality data spanning rounds 1-6 (1998-2013), created in collaboration with the ALPHA Network are available via the DataFirst Repository here - https://www.datafirst.uct.ac.za/dataportal/index.php/catalog/ALPHA/about
